74P The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients (pts) with locally recurrent or metastatic triple-negative breast cancer (TNBC): A multi-cohort, phase II trial. (December 2022) - Liu, L.; Fan, L.; Jin, X.; Xu, Y.; Wu, S.; Yang, Y.; Chen, L.; Zhang, W.; Ma, L.; Hu, X.; Wang, Z.; Jiang, Y.; et al.